Effects of a Cold-Shower Therapeutic Intervention on Symptoms Associated with Depression.

Not Applicable

• Conditions: Depression; Wellbeing; Mental Health - Depression

• Registration Number: ACTRN12622001451796
• Lead Sponsor: Dr. Kairi Kolves

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-11-14
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

Current Griffith University students.

Exclusion Criteria

The following criteria will exclude participants from the study:
•If you have any cardiac disease or condition that through participation in the research, may cause risk of harm to you
•If you have changed medication for any mental illness within the past two weeks

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of depressive symptomology will be assessed utilizing the Depression Anxiety Stress Scale 21 Item (DASS-21) Form.[Baseline, two (primary timepoint) and six-weeks post intervention commencement.];Safety will be assessed by the incidence of adverse events including, but not limited to, reflex hyperventilation as assessed by self-report and light headedness, additionally assessed by self-report. <br>Self-reports will be recorded through Griffith Universities' online survey tool, Limesurvey. Limesurvey questionnaires will be administered online and can be accessed via computer and smartphone.[Safety assessment will be ongoing and assessed during each of the six cold-water therapeutic sessions. Monday, Wednesday and Friday mornings over the two-week trial. ]

Secondary Outcome Measures

Name	Time	Method
Subjective level of wellbeing will be assessed using The World Health Organization – Five item Well-Being Index .[Baseline, two and six-weeks post intervention commencement.];Anxiety will be assessed using the anxiety subscale of the Depression, Anxiety Stress Scale (DASS-21) [Baseline, two and six-weeks post intervention commencement.<br>];Stress will be assessed using the stress subscale of the Depression Anxiety Stress Scale (DASS-21). [Baseline, two and six-weeks post intervention commencement.<br>];The Distress / Endorsement Validation Scale (DEVS), measures subjective levels of treatment distress and participant endorsement of therapeutic protocols.[ Administered at conclusion of the trial, two weeks post-intervention commencement.]